Patrys Ltd
Patrys Limited is an Australia-based company.
The business
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Small Caps Research
No research on Patrys Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PAB based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Patrys Advances RLS-2201 Program with Manufacturing Start and FDA Regulatory Engagement
Patrys kicks off RLS-2201 manufacturing with BioCina and FDA 505(b)(2) engagement, targeting Phase 0 trials in H2 2026.
Patrys releases positive data from deoxymabs study to treat ANCA vasculitis
Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody development company has previously reported non-clinical results that showed the deoxymabs can suppress the formation of neutrophil extracellular traps (NETs), which are structures comprised of […]
Patrys granted Australian patent for Deoxymab platform with nanoparticles to deliver anti-cancer drugs
Therapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent covering the use of its novel Deoxymab platform conjugated to nanoparticles (NP) for the targeted delivery of anti-cancer drugs. The patent is the first of its kind for the local market and covers the use of Deoxymab antibodies PAT-DX1 and PAT-DX3 with […]
Patrys’ lead drug candidate can cross blood brain barrier to target triple-negative breast cancers
A pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown the development drug PAT-DX1-NP is able to cross the blood brain barrier and successfully target triple-negative breast cancer brain metastases. The Yale School of Medicine study found that PAT-DX1-NP administered by tail vein injection in a mouse model of triple-negative breast […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.